Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.50 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.50 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 6/20 | 0.41 |
| ▸ | RAB9A | P51151 | 6/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.41 |
| ▸ | HPGD | P15428 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL98030 | 0.87 | ALDH1A1 (0.73) | ALDH1A1EHMT2EHMT1APOBEC3GMAPT | |
| SCHEMBL29811281 | 0.87 | ALDH1A1 (0.73) | ALDH1A1EHMT2EHMT1APOBEC3GMAPT | |
| SCHEMBL8681802 | 0.85 | ALDH1A1 (0.57) | ALDH1A1EHMT2EHMT1APOBEC3GMAPT | |
| SCHEMBL30308346 | 0.85 | ALDH1A1 (0.71) | ALDH1A1EHMT2EHMT1APOBEC3GMAPT | |
| Succinic Acid SCHEMBL28529727 | 0.85 | ALDH1A1 (0.71) | ALDH1A1EHMT2EHMT1APOBEC3GMAPT | |
| SCHEMBL13739021 | 0.85 | ALDH1A1 (0.57) | ALDH1A1EHMT2EHMT1APOBEC3GMAPT | |
| SCHEMBL76157 | 0.84 | ALDH1A1 (0.55) | ALDH1A1EHMT2EHMT1APOBEC3GMAPT | |
| SCHEMBL10064444 | 0.84 | ALDH1A1 (0.55) | ALDH1A1EHMT2EHMT1APOBEC3GMAPT | |
| SCHEMBL18519250 | 0.84 | ALDH1A1 (0.55) | ALDH1A1EHMT2EHMT1APOBEC3GMAPT | |
| SCHEMBL123215 | 0.83 | ALDH1A1 (0.62) | ALDH1A1EHMT2EHMT1APOBEC3GMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238432-A1 | METHOD FOR GLYCOPROTEIN MODIFICATION | HONEYBEAR BIOSCIENCES INC. (TW) | 2024-07-18 | — | — | US | claimed |
| WO-2024145600-A1 | METHOD FOR GLYCOPROTEIN MODIFICATION | HONEYBEAR BIOSCIENCES INC. (TW) | 2024-07-04 | — | — | WO | claimed |
| CN-110914259-A | Novel water-soluble mono-and di-branched complexing agents and corresponding lanthanide complexes | CISBIO生物试验公司 | 2020-03-24 | — | — | CN | claimed |
| US-20090098574-A1 | FUNCTIONALIZATION OF GOLD NANOPARTICLES WITH ORIENTED PROTEINS, APPLICATION TO THE HIGH-DENSITY LABELLING OF CELL MEMBRANES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) | 2009-04-16 | — | — | US | claimed |
| EP-2018559-A1 | FUNCTIONALIZATION OF GOLD NANOPARTICLES WITH ORIENTED PROTEINS. APPLICATION TO THE HIGH-DENSITY LABELLING OF CELL MEMBRANES | Centre National de la Recherche Scientifique (CNRS) (FR) | 2009-01-28 | — | — | EP | claimed |
| WO-2007122259-A1 | FUNCTIONALIZATION OF GOLD NANOPARTICLES WITH ORIENTED PROTEINS. APPLICATION TO THE HIGH-DENSITY LABELLING OF CELL MEMBRANES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2007-11-01 | — | — | WO | claimed |
| US-20240238432-A1 | METHOD FOR GLYCOPROTEIN MODIFICATION | HONEYBEAR BIOSCIENCES INC. (TW) | 2024-07-18 | — | — | US | disclosed |
| US-20240226322-A1 | FIBRIN-SPECIFIC MATERIALS AND METHODS OF USING THEREOF | NORTH CAROLINA STATE UNIVERSITY | 2024-07-11 | — | — | US | disclosed |
| WO-2024145600-A1 | METHOD FOR GLYCOPROTEIN MODIFICATION | HONEYBEAR BIOSCIENCES INC. (TW) | 2024-07-04 | — | — | WO | disclosed |
| US-11987558-B1 | ALK5 inhibitors and their uses | SYNTHIS THERAPEUTICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20230295338-A1 | A NOVEL ANTIBODY BINDING SPECIFICALLY TO HUMAN CEACAM1/3/5 AND USE THEREOF | YMMUNOBIO AG (CH) | 2023-09-21 | — | — | US | disclosed |
| US-20230132568-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | SYNTHIS THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230090552-A1 | ALK5 INHIBITOR CONJUGATES AND USES THEREOF | SYNTHIS THERAPEUTICS, INC. (US) | 2023-03-23 | — | — | US | disclosed |
| US-6197299-B1 | TARGET CELL IS CONTACTED WITH A TARGET CELL LYSIS EFFECTIVE AMOUNT OF A SOLUBLE MONOCLONAL ANTIBODY OR FRAGMENT CONJUGATE COVALENTLY LINKED BY PEPTIDE BOND LINKAGE TO A SUPERANTIGEN FOR THE LYSIS OF A TARGET CELL BY ASSISTANCE OF LYMPHOCYTES | PHARMACIA & UPJOHN AB (SE) | 2001-03-06 | — | — | US | disclosed |
| WO-1999013918-A2 | ICAM-1 SELECTIVE ECHOGENIC MICROBUBBLES | UNIVERSITY OF PITTSBURGH (US) | 1999-03-25 | — | — | WO | disclosed |
| EP-0610179-B1 | TARGET SPECIFIC ANTIBODY-SUPERANTIGEN CONJUGATES AND THEIR PREPARATION | PHARMACIA AB (SE) | 1996-10-16 | — | — | EP | disclosed |
| EP-0610179-A1 | TARGET SPECIFIC ANTIBODY-SUPERANTIGEN CONJUGATES AND THEIR PREPARATION. | KABI PHARMACIA AB (SE) | 1994-08-17 | — | — | EP | disclosed |
| EP-0540612-A1 | HETEROBIFUNCTIONAL REAGENTS AND CONJUGATES WITH OXAALKYLENE UNITS FOR AMPHIPHILIC BRIDGE STRUCTURES | Pharmacia AB (SE) | 1993-05-12 | — | — | EP | disclosed |
| WO-1992001470-A1 | TARGET SPECIFIC ANTIBODY-SUPERANTIGEN CONJUGATES AND THEIR PREPARATION | KABI PHARMACIA AB (SE) | 1992-02-06 | — | — | WO | disclosed |
| WO-1992001474-A1 | HETEROBIFUNCTIONAL REAGENTS AND CONJUGATES WITH OXAALKYLENE UNITS FOR AMPHIPHILIC BRIDGE STRUCTURES | KABI PHARMACIA AB (SE) | 1992-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11987558-B1 | ALK5 inhibitors and their uses | ALK, ALKBH3, ALKBH5 | ALDH1A1 1041/4885EHMT2 605/4885EHMT1 787/4885 |
| US-20240238432-A1 | METHOD FOR GLYCOPROTEIN MODIFICATION | SIGLEC7, FUT5, FUT6 | ALDH1A1 549/4885EHMT2 2301/4885EHMT1 2800/4885 |
| US-20230090552-A1 | ALK5 INHIBITOR CONJUGATES AND USES THEREOF | ALK, ALKBH5, ALKBH3 | ALDH1A1 297/4885EHMT2 268/4885EHMT1 260/4885 |
| US-20230132568-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | ALK, ALKBH5, ALKBH3 | ALDH1A1 346/4885EHMT2 468/4885EHMT1 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.